Close Menu

Eisai

The Phase III Keynote-775 study has shown that the combination improves overall and progression-free survival compared to chemotherapy.

H3, a subsidiary of Japanese drugmaker Eisai, is developing personalized cancer treatments targeting genomic alterations, including aberrant RNA splicing.